Zobrazeno 1 - 10
of 25
pro vyhledávání: '"David T, Beattie"'
Autor:
Donna Leippe, Rebeca Choy, Gediminas Vidugiris, Hanne Merritt, Kevin T. Mellem, David T. Beattie, Julie C. Ullman, Jolanta Vidugiriene
Publikováno v:
ACS Omega, Vol 9, Iss 30, Pp 33072-33080 (2024)
Externí odkaz:
https://doaj.org/article/313fdf8e581d499293b702ef4a1838a6
Autor:
David T. Beattie, M. Teresa Pulido-Rios, Fei Shen, Melissa Ho, Eva Situ, Pam R. Tsuruda, Patrick Brassil, Melanie Kleinschek, Sharath Hegde
Publikováno v:
Journal of Inflammation, Vol 14, Iss 1, Pp 1-11 (2017)
Abstract Background An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust efficacy in ulcerative c
Externí odkaz:
https://doaj.org/article/d1b63811139649dbba728e06e5dfa193
Autor:
Raj Bhandari, M. Teresa Pulido-Rios, David T Beattie, Reuben Sana, Brihad Abhyankar, Jonathan A. Leighton, Jacky Woo, Richard Graham, Eva Situ, Ravi Ganeshappa, Erik Sandvik, Melanie A. Kleinschek, Whitney Krey, David L. Boyle, Deanna D Nguyen, Julián Panés, William J. Sandborn, Patrick Brassil
Publikováno v:
Journal of Crohn's & Colitis
Journal of Crohn's & colitis, vol 14, iss 9
Journal of Crohn's & colitis, vol 14, iss 9
Background and Aims Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical translation of TD-1473—an oral gut-selective pan-JAK inhibitor—from in
Autor:
Yannan Xi, Terrence F. Satterfield, Rebeca Choy, Tarunmeet Gujral, Eva Situ, Samnang Tep, Vivian Morton, Cecile Yu, Daniel Reiton, Baiwei Lin, Hanne Merritt, Pam Santiago, Bryan Espanol, Ryan A. Dick, Julie C. Ullman, Kevin T. Mellem, Sarah B. Noonberg, Eric M. Green, David J. Morgans, Sanjay J. Chandriani, David T. Beattie
Publikováno v:
Molecular Genetics and Metabolism. 135:S128
Autor:
Julie C. Ullman, Kevin T. Mellem, Yannan Xi, Terrence F. Satterfield, Tarunmeet Gujral, Rebeca Choy, Julian R. Homburger, Hanne Merritt, Daniel Reiton, Samnang Tep, Baiwei Lin, Cecile Yu, Eva Situ, Walter Won, Hannah Powers, Vyas Ramanan, Maarten Hoek, Robert Graham, Sanjay J. Chandriani, Christopher Sinz, Ryan A. Dick, Sarah B. Noonberg, David T. Beattie, David J. Morgans, null Jr, Eric M. Green
Publikováno v:
Molecular Genetics and Metabolism. 135:S122
Autor:
David T Beattie, Scott R Armstrong, Ross G Vickery, Pam eTsuruda, Christina B Campbell, Carrie eRichardson, Julia eMcCullough, Oranee eDaniels, Kathryn eKersey, Yu-Ping eLi, Karl HS Kim
Publikováno v:
Frontiers in Pharmacology, Vol 2 (2011)
This study evaluated the in vitro and in vivo pharmacological properties of TD-8954, a potent and selective 5-HT4 receptor agonist. TD-8954 had high affinity (pKi = 9.4) for human recombinant 5-HT4(c) (h5-HT4(c)) receptors, and selectivity (> 2,000-f
Externí odkaz:
https://doaj.org/article/8b74fc1b5c7847d09963708f3ff40836
Autor:
Scott C. Steffensen, Shinju Obara, Sarah S. Jaw-Tsai, David T. Beattie, Talmage D. Egan, Daniel R. Cook, Shanti M. Amagasu, Thomas E. Jenkins
Publikováno v:
Anesthesiology. 116:1267-1277
Background Propofol can be associated with delayed awakening after prolonged infusion. The aim of this study was to characterize the preclinical pharmacology of AZD-3043, a positive allosteric modulator of the γ-aminobutyric acid type A (GABA(A)) re
Autor:
Gary M. Dunny, Ana Belen Oromendia, Suzanne Grindle, Katie S. Ballering, David T. Beattie, Christopher J. Kristich
Publikováno v:
Journal of Bacteriology. 191:2806-2814
The ability of Enterococcus faecalis to form robust biofilms on host tissues and on abiotic surfaces such as catheters likely plays a major role in the pathogenesis of opportunistic antibiotic-resistant E. faecalis infections and in the transfer of a
Autor:
Henry C. Marsh, Michele D. Picard, Jun Qian, David T. Beattie, David Zopf, Lawrence J. Thomas, Tom Stevenson, Krishnasamy Panneerselvam, Russell A. Hammond, Charles W. Rittershaus, Bi Xu, Robert Bayer
Publikováno v:
Glycobiology. 14:883-893
Recombinant soluble human complement receptor type 1 (sCR1) is a highly glycosylated glycoprotein intended for use as a drug to treat ischemia-reperfusion injury and other complement-mediated diseases and injuries. sCR1-sLe(x) produced in the FT-VI-e
Autor:
David P. Miller, Una S. Ryan, Russell A. Hammond, Henry C. Marsh, Lawrence J. Thomas, Christopher M. Honan, Allan D. Callow, Constance D. Emmett, Carolyn L. Pettey, Michele D. Picard, David T. Beattie, Charles W. Rittershaus, Hedy Adari
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 20:2106-2112
Abstract —Using a vaccine approach, we immunized New Zealand White rabbits with a peptide containing a region of cholesteryl ester transfer protein (CETP) known to be required for neutral lipid transfer function. These rabbits had significantly red